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Purpose: Response to a complex trastuzumab-based regimen is affected by multiple features of 
the tumor and its microenvironment. Developing a predictive algorithm is key to optimizing 
HER2-targeting therapy.
Methods: We analyzed 137 pre-treatment tumors with mRNA-seq and DNA exome sequencing 
from CALGB 40601, a neoadjuvant phase III trial of paclitaxel plus trastuzumab with or without 
lapatinib in stage II-III HER2-positive breast cancer. We adopted an Elastic Net regularized 
regression approach that controls for co-varying features within high-dimensional data. First, we 
applied 517 known gene expression signatures to develop an Elastic Net model to predict pCR, 
which we validated on 143 samples from 4 independent trials. Next, we performed integrative 
analyses incorporating clinicopathologic information with somatic mutation status, DNA copy 
number alterations (CNAs) and gene signatures.
Results: The Elastic Net model using only gene signatures predicted pCR in the validation sets 
(AUC = 0.76). Integrative analyses showed that models containing gene signatures, clinical 
features, and DNA information were better pCR predictors than models containing a single data 
type. Frequently selected variables from the multi-platform models included amplifications of 
chromosome 6p, TP53 mutation, HER2-enriched subtype and immune signatures. Variables 
predicting resistance included Luminal/ER+ features.
Conclusions: Models using RNA only, as well as integrated RNA and DNA models, can predict 
pCR with improved accuracy over clinical variables. Somatic DNA alterations (mutation, CNAs), 
tumor molecular subtype (HER2E, Luminal), and the microenvironment (immune cells) were 
independent predictors of response to trastuzumab and paclitaxel-based regimens. This highlights 
the complexity of predicting response in HER2-positive breast cancer.
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INTRODUCTION
Human epidermal growth factor receptor type 2 (HER2) is overexpressed in ~25% of breast 
cancers. The anti-HER2 antibody trastuzumab reduces mortality in stage I-III disease by 
37% when combined with adjuvant chemotherapy. However, approximately one-fourth of 
these patients experience recurrence within 10 years and ultimately succumb to their 
disease(1). Additional HER2-targeting drugs including lapatinib(2), pertuzumab(3), and 
neratinib(4) have been tested in combination with or following trastuzumab in patients with 
stage I – III HER2-positive breast cancer, with variable impacts on disease-free survival in 
terms of statistical significance but all with modest (less than 3%) absolute effects. These 
results clearly highlight our need to identify those in whom additional therapy is warranted. 
The MINDACT and similar trials suggest that genomic classifiers may help identify patients 
with HER2-negative disease who may be treated with less aggressive regimens(5). The 
identification of a biologic classifier for tailoring therapy in HER2-positive disease would 
also be very valuable.
It is equally true that HER2-positive breast cancer is highly molecularly heterogeneous. 
CALGB 40601(6), and the similar trial NeoALTTO(7), have revealed that gene expression 
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signatures of ESR1 and HER2, molecular intrinsic subtype, and immune cell activation are 
associated with pathological complete response (pCR). Several molecular alterations are 
thought to contribute to trastuzumab resistance, including PIK3CA mutation(6,8,9), PTEN 
loss(10,11), and TP53 mutation(12,13), but these possible biomarkers have been 
inconsistent. In NeoALLTO, mutations in the RhoA pathway were associated with response, 
which has not yet been further examined(14). In addition to tumor influences, immune cell 
gene expression has been independently associated with pCR(6,7), and in retrospective/
prospective trials, tumor infiltrating lymphocytes (TILs) have been predictive of trastuzumab 
benefit(15,16). Currently, HER2 overexpression and/or amplification remains the only 
clinically validated marker to select patients for anti-HER2 therapies.
A number of studies including The Cancer Genome Atlas(17,18) have produced a wealth of 
genomic data and described disease mechanisms. However, there are still two major 
challenges when using clinical trial samples: First, most research studies characterize a 
genomic feature type, such as gene expression, mutation, or copy number, and there are few 
capable of integrating disparate data types that reflect the continuum of cancer biology and 
are simultaneously able to address clinical outcomes. Second, because these studies did not 
utilize samples from prospective clinical trials with prespecified endpoints, they are poorly 
suited to identify or validate novel predictive biomarkers.
By contrast, in this study we utilized two computational approaches of integrative data 
analysis, namely Elastic Net and DawnRank, using the samples obtained from Cancer and 
Leukemia Group B (CALGB) 40601(6), a prospective phase III trial of neoadjuvant 
chemotherapy with trastuzumab, lapatinib or both. In this analysis, we first developed an 
Elastic Net model from gene expression data and applied the model onto four different 
validation datasets. In addition, after combining mutation, DNA copy number alterations, 
and gene expression data with known clinical features, we developed objective 
computational models to identify important determinants of response to trastuzumab-based 
therapy. Our goal was to develop an accurate predictor of response, and at the same time, to 
learn more about the biology of therapeutic response in HER2-positive breast tumors.
PATIENT AND METHODS
CALGB 40601 Study Design and Patients
The study design and clinical results have been previously published(6); CALGB 40601 is 
now part of the Alliance for Clinical Trials in Oncology. A total of 305 women with stage II-
III HER2-positive disease were randomized to receive paclitaxel (T) at 80 mg/m2 weekly for 
16 weeks, with trastuzumab (H, 4 mg/kg loading dose followed by 2 mg/kg), lapatinib (L, 
1500 mg/d), or both (L at 1000 mg/d plus the same dose of H) for 16 weeks. The TL arm 
was closed early based on reports of inferiority and greater toxicity; given that single agent 
lapatinib is not a clinically relevant treatment and the mechanism of action differs 
systematically from conventional H or H+L-based therapy, the TL arm was excluded from 
this analysis. The primary endpoint was pCR, defined as no invasive tumor in the breast, 
which is a surrogate endpoint of survival in HER2-positive breast cancer(19).
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Participants underwent 4 pretreatment 16-gauge core biopsies: 2 cores were placed into 
RNA stabilization product (RNALater™Qiagen, Hilden, Germany), and 2 were placed into 
10% neutral buffered formalin. CALGB 40601 enrolled 305 patients. Figure 1-A shows the 
CONSORT diagram for the subset studied here on the genomic level. We eliminated from 
analysis those patients in whom the RNA or DNA quality was inadequate, those treated on 
the non-trastuzumab arm (TL), and those with Normal-like intrinsic subtype, which consists 
mostly of normal tissues. The final training set consisted of 137 patient samples from TH 
(n= 68) and THL (n= 69) arms; all received trastuzumab-paclitaxel regimens. All 137 
patients signed an IRB-approved, protocol-specific informed consent document in 
accordance with federal and institutional guidelines. This document included consent for the 
use of RNA and DNA; the consent also covered future biomarker research. DNA exome 
sequencing was performed at McDonnell Genome Institute (Washington University) and 
RNA-seq was performed at the UNC High Throughput Sequencing Facility (University of 
North Carolina). The patient and tumor characteristics of the included samples did not differ 
significantly from the total dataset (N = 285) including stage, hormonal receptor status, and 
pCR rates (data not shown).
Gene expression and signatures
Gene expression profiles were generated by mRNA-sequencing using an Illumina HiSeq 
2000 as described in Ciriello et al.(17). Briefly, mRNAseq libraries were made from total 
RNA using the Illumina TruSeq mRNA sample preparation kit and sequenced on an 
Illumina HiSeq 2000 using a 2×50bp configuration with an average of 136 million reads per 
sample. Quality-control-passed reads were aligned to the human reference genome (hg19) 
using MapSplice(20). The alignment profile was determined by Picard Tools v1.64 (http://
broadinstitute.github.io/picard/). Aligned reads were sorted and indexed using SAMtools 
and translated to transcriptome coordinates then filtered for indels, large inserts, and zero 
mapping quality using UBU v1.0 (https://github.com/mozack/ubu). Transcript abundance 
estimates for each sample were performed using RSEM, an expectation-maximization 
algorithm(21) using the UCSC knownGene transcript and gene definitions. Raw RSEM read 
counts for all mRNAseq samples were normalized to a fixed upper quartile.
Next, PAM50 subtyping was applied to the gene expression data using a two-step 
normalization process based on the TCGA(17) cohort as previously described(6). We next 
applied a collection of 517 gene expression signatures, representing multiple biological 
pathways and cell types, to all 137 samples. These 517 signatures (all published) were 
obtained from 73 publications or Gene Set Enrichment Analysis (GSEA)(22) and partially 
summarized by Fan, et al.(23) (see eTable 1 for the complete list of signatures and their 
associated references). Using the combined normalized data set with the TCGA data, we 
applied each signature to the data set in a manner consistent with their derivation. For 478 
signatures with homogenous expression across genes within a given set, these represent 
coordinately regulated sets of either “up” genes, or sets of “down” genes. All the genes were 
moving in the same direction, therefore we took the median expression value for all genes in 
a signature. For 39 signatures where gene expression patterns were not homogenous, we 
calculated correlations to predetermined centroids using previously published training 
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datasets/centroids, or used predetermined special algorithms following their original 
methods.
Mutation data
We performed hybrid capture exome sequencing on 137 of the tumors (Nimblegen v3.0 
SeqCap reagent) and matched peripheral blood mononuclear cells (PBMC) sequenced to 
average 100x depth coverage using paired-end 2×100bp. Raw sequences were aligned using 
the BWA-mem algorithm, and refined using our Assembly Based Re-Alignment (ABRA)
(24) process to allow for accurate alignment of complex sequence variation. Somatic 
mutation detection was performed by integrated whole DNA exome and mRNAseq using the 
UNCeqR analytic tool as previously described(25,26).
Copy number variants
Copy number variation across the genome was determined as follows: The sequence reads 
were aligned to the genome (hg 19) using the bwa-mem algorithm (https://github.com/lh3/
bwa; v0.7.4) with the default parameters. Duplicates were removed using Picard (http://
broadinstitute.github.io/picard/). Quality statistics were also generated with Picard including 
measures of fragment length, sequence content, alignment, capture bias and efficiency, 
coverage, and variant call metrics. Copy number assessments were performed using 
SynthEx(27). In brief, counts data for fixed 100kb bins were generated using BEDTools(28). 
The read ratios were calculated using the “synthetic normal” strategy described in SynthEx. 
A trending filter procedure was applied to segment the genome. The segment-level copy 
number values, which are the log2 ratios of normalized signal intensities between tumor and 
controls, were finally corrected by purity and ploidy estimates from SynthEx, taking whole 
genome doubling into account for these values. These segment-level values were changed 
into gene-level values using Switchplus(29), and then we re-calculated the values for 536 
predetermined cancer-specific segments (eTable 2) that are frequently altered in multiple 
types of cancer including breast cancers(30,31); we also calculated chromosome arm based 
values and included these as features (48 segments). DNA Copy number values derived from 
exome sequencing were compared with those from SNP6.0 among the TCGA samples(17) 
with ploidy 1.75 – 2.5, then the thresholds for gain or loss from exome-derived SynthEx 
values were determined as 0.25 or −0.32, respectively(27); we applied these thresholds to 
copy number values on the CALGB 40601 samples to call gained and lost segments.
The complete list of DNA mutation somatic variants, DNA copy number segment, and gene 
expression values from CALGB 40601 samples are provided in Supplementray Data Files 
1–3. The accession number for the RNAseq data for CALGB 40601 is GSE116335. Exome 
data for CALGB 40601 cohort is available via the NCBI dbGAP repository under accession 
number phs001570.v1.
Statistical analyses
All statistical analyses were performed using R version 3.1.2. All analyses were based on the 
study database frozen on January 29, 2016.
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Elastic Net analysis—For feature selection using a multivariate modeling approach, we 
used Elastic Net (R package glmnet)(32), which is a regularized regression method that 
linearly combines the L1 and L2 penalties of the Ridge Regression and Least Absolute 
Shrinkage and Selection Operator (LASSO)(33). Monte-Carlo cross-validation(34) (R 
package caret) was conducted using 200 different training sets randomly selected from the 
137-sample training set. Models were built to predict pCR in the training set, selecting 
lambda values over a grid of alpha values from 0.1 to 1 by 0.1 increments via 10-fold cross 
validation(35) (R package glmnet). Then we calculated accuracy, which equals (sensitivity + 
specificity) / 2, for each parameter combination. We identified the optimal parameter 
combination with the highest accuracy during cross-validation, and applied this to the final 
model using the best parameter combination onto the test set, and then constructed ROC 
curves and evaluated area under ROC (AUC). The variables with a high or low (negative) 
coefficient value would be associated with response or resistance to trastuzumab-containing 
therapy, respectively.
There were two purposes for the Elastic Net analyses, namely model-building and biological 
discovery through feature selection. First, we wished to evaluate the robustness of the Elastic 
Net model and use of this approach for pCR prediction. We developed the predictive model 
using 137 tumors from the CALGB 40601 training set and validated it using gene expression 
datasets from an independent group of 143 patients who participated in four clinical trials of 
neoadjuvant chemotherapy plus trastuzumab for patients with HER2-positive breast cancer 
on whom high-quality gene expression data were available. These included 43 patients in 
CHERLOB(8) who received anthracycline, taxane, and trastuzumab, with or without 
lapatinib; 24 patients in XENA(36) who received capecitabine, taxane, and trastuzumab; 10 
patients in I-SPY1(37) who received anthracycline, taxane, and trastuzumab; and 66 patients 
from the CALGB 40601 independent validation set who received taxane and trastuzumab 
with or without without lapatinib, but who were not included in the training set (because the 
training set was limited to those with RNA and DNA genomics). All the patients received at 
least trastuzumab and taxane. Supplementary Figure 1-A diagrams the overall process of the 
Elastic Net model development and evaluation. In more detail, the gene signature data of all 
137 samples from the CALGB 40601 training set were used as the training dataset to 
construct a model for an expression-only pCR prediction. This model was applied to 
CHERLOB, XENA, I-SPY, the CALGB 40601 independent validation set and all four test 
sets combined to construct ROC curves and evaluate AUC.
Second, in order to identify important and novel features contributing to sensitivity and 
resistance using a multi-dimensional approach, we investigated combining mutation, DNA 
copy number, and gene expression data with known clinical features, and then used all of 
these features for Elastic Net model building. Mutation and copy number alterations (CNAs) 
were used as dichotomous and continuous variables, respectively. By balancing for 
clinicopathological features, the samples were divided into a training and a test set (R 
package sampling), then Monte-Carlo cross-validation was conducted using 200 different 
training sets randomly selected from the larger training set. We developed a set of integrated 
Elatic Net regression models to predict pCR, varying the features used as input. Because this 
component of the study was limited to available samples with both RNA and DNA data, 
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which limited sample size, the Elastic Net was performed using 10 rounds of training and 
testing. The most frequently selected features in the models were identified in order to find 
reproducible predictive features (Supplementary Figure 1-B).
Survival analysis on METABRIC samples—In order to address the behavior of these 
models in HER2-positive tumors that did not receive trastuzumab or other HER2-targeted 
agents, thereby eliminating variables unrelated to HER2-directed therapy, the Elastic Net 
gene expression-only models from CALGB 40601 were applied onto 216 HER2-positive 
tumors from the METABRIC(38) dataset from the pre-trastuzumab era. Among the 216 
patients studied, 124 did not receive either chemotherapy or HER2-targeting, and 92 
received chemotherapy without trastuzumab. The median follow-up period was 7.24 (0.15–
26.90) years. The patients were classified into three groups according to the scores derived 
from the expression only Elastic Net model, and overall survival was assessed by the 
Kaplan-Meier method.
DawnRank analysis—We used DawnRank(39), a novel computational method that uses 
within-tumor integrated analyses based upon predetermined protein-protein interactions 
networks, then populated by patient specific tumor gene expression values, and DNA 
aberrations, in order to identify those genes with DNA aberrations that have the greatest 
expression impact on the predefined networks; these Dawnrank scores are calculated on 
individual patients, then aggregated based upon groups of patients, to find individual genes 
involved in response to trastuzumab-containing therapies. Using the DawnRank predefined 
protein-protein interaction networks, we populated this network with mRNA gene 
expression data for each patient and calculated a score for each gene based upon the 
expression of the genes directly connected to it in the network. The DawnRank score(s) 
depend on the three parameters: predetermined protein-protein interaction networks, gene 
expression values for each patient, and a “damping factor” that represents the extent to 
which the ranking depends on the structure of the network. These three parameters along 
with DNA alteration status (i.e. mutation, amplification, or deletion) form the key 
components to determine “drivers” in individual samples. Log2 transformed normalized 
mRNAseq gene expression data were median-centered for each gene among 137 CALGB 
40601 samples, and further transformed to absolute value scores. Dawnrank was then run for 
each tumor with a mu = 3, which is the suggested default setting. The genes were then 
ranked according to the Dawnrank scores.
We then generated a binary matrix of 0 indicating no alteration and 1 indicating any DNA 
alteration for each gene, and examined somatically altered genes (DNA mutations and/or 
DNA alterations as described above) by applying DawnRank to the samples with pCR vs 
those without pCR according to the “percentrank” analysis mode, which aggregates the 
DawnRank results across a predefined set of samples/patients in order to find drivers based 
upon groups of patients (i.e. those with a pCR). Briefly, DawnRank applies a modified 
version of the Condorcet method(40), which is a voting scheme selecting a winning 
candidate gene by comparing every possible pair of candidate genes. Therefore a pair of 
candidate genes A and B are compared by the number of alterations in gene A that had 
higher Dawnrank scores than gene B.
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The association between pCR status and the clinicopathological variables, or mutated genes, 
were investigated using Fisher’s Exact test with Bonferroni correction. Using a two-class 
unpaired Significance Analysis of Microarrays (SAM)(41), we also conducted a 
permutation-based, supervised analysis to find features with significant correlation to pCR 
by comparing pCR samples versus non-pCR samples using gene-level DNA copy number 
data.
Hierarchical clustering was performed using centroid linkage implemented in software Gene 
Cluster 3.0(42), and the clustering result was viewed with Java Treeview v1.1.5r2(43) to 
identify patterns among the features selected in the Elastic Net models. We investigated the 
significance of gene signatures with unknown roles using the “Investigate Gene Sets” 
method of Gene Set Enrichment Analysis (GSEA, http://software.broadinstitute.org/gsea/
msigdb/annotate.jsp)(22), and also investigated gene signature scores according to PAM50 
subtype among 1100 breast cancer patients from TCGA(17). ROC/AUC curves were 
compared using R package pROC(44). DNA copy number frequency landscapes were 
generated using Swicthplus(29), which can identify segments with CNAs specific for a user-
determined set of tumors, in this case, samples with pCR vs non-pCR. Thus Switchplus 
provides a supervised method for analysing and visualizing copy number data. Switchplus is 
provided as a source script in R and available for download at: https://genome.unc.edu/
SWITCHplus/.
RESULTS
Cohort characteristics and genomic datasets
On CALGB 40601 specimens, we performed mRNAseq and DNA exomes (N=137, Figure 
1-A. We compared non-silent mutation frequencies between HER2-positive breast cancer in 
TCGA (N=145) and tumors in CALGB 40601 (N=137). Although PIK3CA and CDH1 
mutation were more frequent in TCGA HER2+, there were no differences in the list of 
somatically mutated genes between these two studies after Bonferroni correction 
(Supplementary Figure 2-A). We also confirmed the similarity between TCGA HER2+ and 
CALGB 40601 by comparing their DNA copy number frequency landscapes 
(Supplementary Figure 2-B), and again the results showed very high similarity. Among 
10816 non-silent mutations found through exome sequencing of 137 CALGB 40601 tumors, 
5106 mutations (47.2%) were detected in the mRNAseq of the corresponding tumors by 
UNCeqR(26). This frequency is comparable to the 51% frequency seen when performing 
the same analysis using 871 TCGA lung and breast cancer samples(26).
Among the 137 samples studied on the genomic level in CALGB 40601, clinical estrogen 
receptor (ER) or progesterone receptor (PgR) status and intrinsic subtype by PAM50 were 
associated with pCR (Figure 1-B). eTable 3 shows the list of somatically mutated genes with 
a frequency of >4%, and where only 8 genes occurred in ≥10 patients (≥7 %), and only 
TP53 mutation status was associated with pCR after Bonferroni correction (eTable 3). 
Interestingly, there were 4 patients with HER2 somatic mutations, including 2 with a variant 
allele frequency of greater than 10%; these two included a V777L variant, and a L755S 
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variant. The V777L variant is predicted to be activating and sensitive to lapatinib(45); this 
patient was in the THL arm and achieved a pCR. The L755S variant is predicted to be 
transforming, but insensitive to lapatinib; this patient was in the TL arm and had residual 
disease after therapy. As a resource, multiple individual data type supervised analyses were 
performed on the 40601 training data set and present as eTable 4; these include results of the 
supervised analyses using individual gene expression values, gene signatures, DNA 
segment-level copy number, or gene-level copy number data. Likewise, The supervised 
results on CALGB 40601 validation set using gene-expression and gene signatures are listed 
on eTable 5.
Gene expression based prediction of pCR using Elastic Net
We first developed genomic predictors of response to trastuzumab containing regimens using 
gene expression alone because several validation sets existed that would allow us to develop, 
then validate, a predictive model based on RNA data. Therefore, we used the Elastic Net 
method to develop a model for predicting pCR and starting with 517 published expression 
signatures applied to the 137 patient CALGB 40601 training cohort (Supplementary Figure 
1, and Table 1). Included within the positive predictive features were several well-described 
signatures including “correlation to HER2-Enriched”, two breast cancer recurrence 
predictors(46,47), and immune signatures. On the other hand, the tumor’s ER status based 
on clinical assay (cER), the signature of “correlation to luminal A” and a PgR-activity gene 
signature were negative predictors of pCR. For gene signatures of interest with unknown 
functions, we used GSEA(22) to gain insight into their function. “HS_Green18” (False 
discovery rate [FDR] = 3.3e-60) and “HS_Red19” (FDR = 2.6e-52) were correlated with the 
Luminal B signature and highly expressed in Luminal TCGA tumors(17). “HS_Red12” 
correlated with the HER2 signature in GSEA (FDR = 3.7e-115) and was highly expressed in 
TCGA HER2-Enriched tumors (Supplementary Figure 3-A to C). The optimized predictive 
model using gene expression signatures alone was applied to the CHERLOB(8), XENA(36), 
I-SPY1(37), and additional CALGB 40601 validation data sets, and all four sets combined 
(test sets). The AUC values were 0.80 (training), 0.73, 0.71, 0.83, 0.78 and 0.76 (combined); 
pCR rates in the test sets ranged from 13% in the lowest tertile scores, to 65% in the highest 
tertile (Figure 2, details in Supplementary Figure 4 and eTable 6).
Elastic Net analysis using multi-dimensional data
We hypothesized the comprehensive integration of DNA copy number aberrations and 
mutations, added to gene expression and clinical data, would further improve predictive 
ability for response to trastuzumab-based therapy. The integrated Elastic Net multi-
dimensional modeling assessed 528 DNA copy number segment values using 536 predefined 
chromosomal segments, 8 genes with somatic mutations in ≥10 patients, and the 517 gene 
expression signatures. Clinical ER and PgR status were included given consistent 
associations with pCR in HER2-positive breast cancer trials(6,7). Figure 3-A shows the 
average AUC values for each unique set of input variables in 10 rounds of repeated Elastic 
Net analysis (details in eTable 7). The model derived from the combination of gene 
signatures and CNAs yielded an AUC of 0.76, which was significantly higher than those 
from each individual data type alone (p <0.05). Gene signatures and CNAs were further 
combined with either mutation and/or clinical ER/PgR status, but the AUC values did not 
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change significantly. The integrated Elastic Net models largely overlapped the signatures 
identified in the gene signatures-only model (Table 1). We finally selected the combination 
of gene signatures, CNAs, mutation and clinical ER/PgR status with the average AUC of 
0.75 as the model to most fully explore, because of its objective integration of multiple data 
types, including TP53 mutation(25), and ER status(7), which have been previously reported 
as pCR predictors in patients receiving trastuzumab-based regimens. Using serial rounds of 
training and testing, we identified 33 features that contributed to ≥6 out of the 10 rounds of 
Elastic Net models using this combination of many distint feature types (Figure 3-B, all 
features in eTable 8). Included within the most frequently selected positive predictors in the 
integrated analysis were CNAs at chromosome (Chr.) 6p, TP53 mutation status, the 
signatures of Correlation to HER2-Enriched, 21-gene Recurrence Score(46), and 2 immune 
signatures of B-cells. On the other hand, clinical ER status, the signature of Correlation to 
Luminal A and of PgR-activity remained as negative predictors.
We further conducted supervised clustering of the 33 features among the 137 samples 
(Figure 4). The features were clustered into two dendrogram nodes according to positive or 
negative predictors of pCR. The positive features were further aggregated by DNA copy 
number segments at 6p and 22q, and a grouping of the recurrence predictors, TP53 mutation 
status, and HER2 signatures. Estrogen-related features as negative predictors including 
clinical ER status, PgR signature and Correlation to Luminal A, were also clustered together. 
The samples were next ordered by their average scores derived from the 10 rounds of Elastic 
Net modeling. The model scores were highly correlated with pCR (logistic regression odds 
ratio, 1.6; p < 0.001). When samples were trichotomized into top, middle, or lower tertile 
groups of the model scores, pCR rates were 93.4%, 44.4%, and 6.5%, respectively.
Survival analysis
The Elastic Net models using gene signatures with/without mutation (i.e. TP53) plus 
ER/PgR from CALGB 40601 (Table 1 and eTable 9) were applied onto 124 HER2-positive 
tumors from the METABRIC(38) dataset who did not receive any chemotherapy or 
trastuzumab, and onto 92 HER2-positive tumors from METABRIC(38) who received 
chemotherapy but no trastuzumab from the pre-trastuzumab era. Neither of these two 
models was prognostic (Supplementary Figure 5-A and 5-B) suggesting that these models 
largely reflect prediction of response to HER2-targeting.
DawnRank analysis
We next ran DawnRank(39), a computational method that uses RNA expression to populate 
known protein-protein networks, to identify those genetic alterations that alter these 
networks the most. Using the protein-protein networks comprising 8,248 genes and 
aggregating the individual patient results based upon those with a pCR and those without a 
pCR (eTable 10), we sought to identify the genetic drivers of response and resistance. HER2 
and TP53, which are regarded as major genetic drivers in breast cancer, were ranked as No.1 
or 2 in both pCR and non-pCR samples, supporting the robustness of the analysis, and the 
importance of TP53 regardless of treatment and response. Next, we extracted the top 1% of 
the genes from these rankings, then further ranked these genes according to the extent of 
rank change between pCR and non-pCR samples in order to identify those genes that qualify 
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as drivers differentially present in either responsive (pCR) or resistant (non-pCR) tumors 
(eTable 11). Among pCR samples, amplified Chr.6p genes were highly ranked compared 
with non-pCR samples, while deleted Chr.11q genes were highly ranked in non-pCR 
samples compared with pCR samples.
Identification of gene-level CNAs as candidate biomarkers of trastuzumab resistance/
sensitivity
By comparing the DNA copy number landscape plots of pCR vs non-pCR samples (Figure 
5-A), we found that gain of Chr.6p12–21 were more frequent in pCR samples, while loss of 
Chr.22q11–13 were more frequent in non-pCR samples. We next performed computational 
analysis to find common drivers between 1) copy number altered genes in segments 
contributing to ≥6 out of the 10 Elastic Net models, 2) the top 1% copy number-altered 
genes from the DawnRank, and 3) copy number-altered genes with FDR ≤ 1% from SAM 
analysis (eTable 4). Only MAPK14 and CDKN1A at Chr.6p were identified in all three 
analyses (Figure 5-B, overlapped genes are listed in eTable 12). This small amount of 
overlap between the Dawnrank results and other analyses may be because Dawnrank is 
limited to the 8000 genes in the protein-protein interaction network, or other unknown 
reasons. Further only MAPK14 had a Pearson correlation ≥0.3 between RNA gene 
expression and DNA copy number values (MAPK14, 0.38 and CDKN1A, −0.08). Therefore, 
amplification of wild type MAKP14 (also known as p38), may play a direct role in 
sensitivity to trastuzumab/paclitaxel-based regimens, but experimental validation is needed.
DISCUSSION
To our knowledge, this study represents one of the first multi-dimensional genomic analyses 
to integrate DNA mutations, DNA copy number aberrations, and RNA transcriptional 
expression with clinical variables using prospectively collected frozen tissue samples from a 
Phase III trial to predict the primary endpoint of the parent trial, pCR. The importance of 
this approach was suggested at the time we published the primary multivariable analysis of 
CALGB 40601, in which we found that treatment arm was associated with pCR, but also 
that gene signatures representing tumor and microenvironmental influences, such as intrinsic 
subtype and signatures representing activated B-cells, each independently and significantly 
contributed to pCR, regardless of treatment arm; similar results were found in NeoALTTO, 
but integrated models were not developed6,7. We found that the most highly correlated 
negative predictive variables included signatures of the luminal subtypes(7,48), which have 
been consistently reported as negative pCR predictors and were again in this multi-signature 
model, while the HER2-enriched subtype(7,48) and activated immune signatures(7) were 
positive predictors here and in other neoadjuvant trials. These commonalities across studies 
support the robustness of our results. The predictive model based on gene signatures alone 
achieved good AUC values of 0.76 (0.71 – 0.83) in the four validation datasets. In actual 
performance, the low model score tumors had a pCR rate of 13%, and given the association 
of residual disease with poor outcome, these are tumors that may need additional therapies 
to achieve higher pCR rates and better outcomes. Conversely, the group with high model 
scores showed a high response rate of 65%, suggesting that most of these tumors may be 
receiving adequate treatment with trastuzumab and paclitaxel (Figure 2). Because all 137 
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patients used for this analysis received at least paclitaxel plus trasuzumab, it is difficult to 
separate our predictive features for responsiveness to either paclitaxel or trastuzumab. 
However, this combination is part of standard neoadjuvant chemotherapy regimens for stage 
II – III HER2-positive breast cancer and is an accepted and low toxicity regimen known to 
provide distant-disease free survival in excess of 98% for stage I HER2-positive breast 
cancer(49). It is worth noting that in the one prognostic dataset available, the Elastic Net 
models were not prognostic in either HER2-positive patients who did not receive 
chemotherapy nor those who received chemotherapy without trastuzumab. These results 
suggest that our Elastic Net predictors are not prognostic but truly predictive of drug 
response. An algorithm integrating relevant genomic predictors, with clinical features, may 
therefore allow us to safely de-escalate therapy in appropriate patients just as we do with 
hormone receptor-positive, HER2-negative patients by using commercial genomic assays.
Much of precision medicine is founded upon linking somatic mutations to targeted 
treatments, however, we found only 8 genes mutated in ≥10/137 patients; we did find two 
high VAF HER2 mutants, where one achieved a pCR and the other did not, thus 
foreshadowing the complexities of predicting response in single target based “basket 
studies”(50). These overall mutation results are comparable to those from a similar 
neoadjuvant study(14) in which only PIK3CA mutation was associated with lower pCR 
rates. In our study, only TP53 gene mutation was associated with higher pCR rates with 
support from two p53 mutation signatures also selected in the Elastic Net approach. 
Additional encouraging data arose from copy number evaluations; both the Elastic Net and 
DawnRank analyses made use of the multi-dimensional genomic data and found gain of Chr.
6p as a key determinant of sensitivity to trastuzumab-based regimens. Further analysis on 
the gene-level copy number basis identified amplification of MAPK14 at Chr.6p as being 
linked to a high likelihood of pCR (Figure 5). The p38 MAPK pathway is activated upon 
cellular stress and engages pathways that can promote apoptosis(51). Activation of p38 
MAPK pathway impaired mammary carcinogenesis in a HER2-positive mouse model(52). 
Therefore, we hypothesized that trastuzumab-paclitaxel regimens cause stress and that 
MAPK14 amplification may lead cancer cells to undergo apoptosis and is a potential 
response biomarker for trastuzumab-paclitaxel containing regimens. We also take note of 
human leucocyte antigen (HLA) genes because Chr.6p contains all the HLA genes and both 
the Elastic Net and SAM analysis contained 11 HLA genes (Supplementary eTable 12). 
Thus, amplification of HLA genes may be involved in the immune response.
The strengths of our analyses were that these studies were performed on prospectively 
collected frozen tissue samples from a randomized Phase III trial with pCR as the primary 
endpoint. The Elastic Net gene signature-only model was tested on four different 
independent validation datasets, and the model predicted pCR with good accuracy on all 
four. Two types of integrated genomic analyses, Elastic Net and DawnRank, were performed 
to make use of the multidimensional genomic data, with similar results obtained from each. 
The weaknesses of our approach were that we lacked an independent validation set for the 
integrated RNA and DNA Elastic Net predictor, although we did test our methods using 10 
rounds of Monte-Carlo training and testing within CALGB 40601 data, and we report these 
values, that our sample size was relatively small, and that we cannot address the holy grail of 
anti-HER2 regimens without chemotherapy (although the absence of correlation with 
Tanioka et al. Page 12













outcome in chemotherapy-only treated independent datasets suggests that our findings 
reflect the HER2-targeted element); we would need to test these models in all-biologic 
HER2-based regimens.
Collectively, tumor genetics (mutations, CNAs), tumor mRNA subtype (HER2-enriched, 
Luminal), and the microenvironment (Bcell features) were independently predictive of 
response to trastuzumab-paclitaxel containing therapies for HER2-overexpressing breast 
cancer. Elastic Net analysis represents a promising means of developing predictors of pCR 
for clinical application in part due to its objective ability to select from amongst multiple 
data types. Additional studies are needed to fully evaluate these multi-platform predictors, 
but it is clear that integrating all the relevant data types together can improve our predictive 
abilities and may contribute to rational tailoring approaches for the treatment of HER2-
positive breast cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Response to the increasingly complex trastuzumab-based regimens used in women with 
HER2-positive breast cancer is affected by multiple clinical and genomic features 
including immunohistochemical ER positivity, immune cell signatures, and molecular 
intrinsic subtype. Developing an integrated prediction model of pathologic complete 
response (pCR) using multi-dimensional genomic data could be key to optimizing HER2-
targeting therapy. Here, we applied 517 known gene expression signatures to develop an 
Elastic Net model with high predictive capability for pCR, which we validated in 4 
independent clinical trials. The model included HER2-enriched subtype, immune cell and 
Luminal/ER features. We further performed integrated analyses incorporating 
clinicopathologic information with somatic mutation status, DNA copy number 
alterations (CNAs), and found similar expression features and DNA amplifications of 
chromosome 6p as a strong predictors of pCR. This highlights the complexity of 
predicting response and suggests that optimal models to predict response many require 
multiple data types in addition to the standard clinical features.
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Figure1. CONSORT diagram of patient selection and characteristics.
(A) Sample flow chart to show how samples were selected. Starting with 305 patients, 
specimens were removed for multiple reasons including incomplete clinical data, low RNA 
yields, a normal-like non-tumor expression profile, being part of the TL= lapatinib and 
paclitaxel arm, thus leaving 203 patients. Of these, 137 had DNA exomes results, with this 
final 137 sample set also being split into a training and test set. (B) Clinical and intrinsic 
expression subtype characteristics with pCR rates using the 137 patient data set. P-values 
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were calculated by Chi-aquare test. TH, trastuzumab and paclitaxel arm; THL, trastuzumab, 
lapatinib and paclitaxel arm; ER, estrogen-receptor; PgR, progesterone receptor.
Tanioka et al. Page 19













Figure 2. Performance of the Elastic Net model for pCR prediction using gene signatures on 
CALGB 40601.
(A) Area under the curve (AUC) from the Receiver operating characteristic curve analysis 
were estimated for Elastic Net models using gene signatures alone in CALGB 40601. Left, 
CALGB 40601 as the training set (N = 137), AUC = 0.80; Right, All test sets combined 
(CHERLOB + XENA + I-SPY + CALGB 40601 validation set, N= 143, AUC = 0.76). 
Sensitivity and specificity values were selected using Youden’s cutpoint where the sum of 
sensitivity and specificity is maximal. Mann-Whitney-Wilcoxon test was conduct to 
calculate p-values. (B) Barplots showing results of the Elastic Net model score split into 
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three rank order groups and then comparing pCR rates for patients in CALGB 40601, or all 
test sets combined. ANOVA T-test was conducted to calculate p-values by comparing 
signature scores across all three groups.
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Figure 3. Elastic Net analysis using multi-dimensional data.
(A) Average AUC scores for various individual data type, or combined data type predictors, 
using test sets through 10 repeated Elastic Net analyses. Each bar shows the average AUC 
scores with 95% confidence intervals. (B) Frequently selected Elastic Net features coming 
from a multi-dimensional predictor. Features contributing to at least 6 out of 10 Elastic Net 
models using gene signatures, CNAs, mutations, and clinical ER/PgR status. GS, gene 
signature; CN, copy number; Mut, mutation; Gray and black bars indicate predictors which 
positively (37) and negatively (53) predict pCR; thus gray predictors are high in pCR 
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samples and black predictors are high in non-pCR samples. Yellow arrows indicate CNAs 
features at Chromosome 6p; Green arrows indicate TP53 mutation status or signatures; Pink 
arrows indicate HER2-enriched signatures; A gray arrow indicates 21-gene Recurrence 
Score; Black arrows indicate immune signatures; Blue arrows indicate Clinical ER status, 
Luminal signatures and PgR gene signature.
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Figure 4. Hierarchical clustering of multi-dimensional features associated with pCR.
Supervised clustering of the 33 selected features among 137 samples. The features were 
grouped into two clusters with positive or negative predictors. The samples from left to right 
were ordered by their average scores derived from the 10 Elastic Net models grouped into 
high, middle, and low scores.
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Figure 5. Identification of DNA copy number alterations as biomarkers of trastuzumab-
paclitaxel resistance and sensitivity.
(A) DNA copy number frequency landscape plots for pCR vs non-pCR tumors. The 
frequency of alterations in each group is indicated on the y-axis from 0 to 100 %. Segments 
of group-specific copy number gains or loss are plotted above or below the x-axis, 
respectively. Significantly different regions between pCR vs. non-pCR (t-test p<0.05 after 
Benjamini and Hochberg correction) are highlighted in red (gain) or in green (loss). (B) A 
Venn diagram comparing three types of gene-level copy number results. Genes in copy 
number segments contributing to ≥6 models out of the 10 Elastic Net testing, top 1% copy 
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number genes from the Dawnrank analysis, and copy number genes with false discovery rate 
≤ 1% from SAM analysis were plotted and identify MAPK14 and CDKN1A as possible 
driver genes for trastuzumab-paclitaxel sensitivity.
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Table 1.






























Using Elastic Net feature selection, features that made the logistic regression model are shown in this table. All the selected features are weighted 
and show non-zero coefficient values where positive coefficients predict pCR and negative coefficients predict non-pCR. GS, gene signature; HS, 
homo sapiens; MM, mammary model; PgR, progesterone receptor; Wt, wild type; Mut, mutation
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